{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:36:19Z","timestamp":1794656179825,"version":"4.9.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ulcerative colitis (UC) is one of the two major types of inflammatory bowel disease (IBD), characterized by inflammation of the colon and rectum. The colorectal epithelium, which covers the mucosal surface, maintains homeostasis by supporting commensal microorganisms in the outer mucus layer. Most colorectal epithelial cells (CECs) are absorptive colonocytes distributed primarily in the upper portion of the crypts. These CECs constitute the front-line barrier that modulates mucosal immunity and facilitates the transfer of immune molecules into the lumen. In patients with UC, CECs undergo both apoptosis and pyroptosis. Apoptosis is a physiological, programmed, caspase-dependent, and tightly regulated form of cell death that eliminates aged and damaged cells. In contrast, pyroptosis is an inflammatory, caspase-dependent form of lytic cell death that occurs in response to harmful stressors and toxins. Pyroptosis in CECs involves a broad array of signaling and effector molecules, many of which serve as measurable biomarkers with diagnostic, prognostic, and therapeutic potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dysregulated colorectal microflora significantly contributes to activating the pyroptotic pathway, initiating an inflammasome- and gasdermin-dependent inflammatory cell death process in UC patients. This review discusses the triggers and pathways of pyroptosis in CECs, evaluates recently identified biomarkers, highlights their potential roles in pyroptosis and as therapeutic targets in managing UC, and candidate compounds that have been shown effective UC therapeutics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12929-025-01206-x","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:37:21Z","timestamp":1764740241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pyroptosis in ulcerative colitis: biomarkers and therapeutic targets"],"prefix":"10.1186","volume":"32","author":[{"given":"Hannah","family":"Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prarthna","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Wohlgemuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ketchum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Nassif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9741-411X","authenticated-orcid":false,"given":"Chien-An A.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"10401","key":"1206_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"12","author":"CL Berre","year":"2023","unstructured":"Berre CL, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;12(10401):571\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(23)00966-2.","journal-title":"Lancet"},{"issue":"3","key":"1206_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline in adults. Am J Gastroenterol. 2019;114(3):384\u2013413. https:\/\/doi.org\/10.14309\/ajg.0000000000000152.","journal-title":"Am J Gastroenterol"},{"key":"1206_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2019.02.004","author":"M Gajendran","year":"2019","unstructured":"Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019. https:\/\/doi.org\/10.1016\/j.disamonth.2019.02.004.","journal-title":"Dis Mon"},{"key":"1206_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5363261","volume":"3","author":"Q Zhou","year":"2019","unstructured":"Zhou Q, Shen ZF, Wu BS, Xu CB, He ZQ, Chen T, et al. Risk of colorectal cancer in ulcerative colitis patients: a systematic review and meta-analysis. Gastroenterol Res Pract. 2019;3:5363261. https:\/\/doi.org\/10.1155\/2019\/5363261.","journal-title":"Gastroenterol Res Pract"},{"key":"1206_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.951004","volume":"13","author":"T Zhang","year":"2022","unstructured":"Zhang T, Zhang B, Tian W, Wang F, Zhang J, Ma X, et al. Research trends in ulcerative colitis: a bibliometric and visualized study from 2011 to 2021. Front Pharmacol. 2022;13:951004. https:\/\/doi.org\/10.3389\/fphar.2022.951004.","journal-title":"Front Pharmacol"},{"key":"1206_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00985-0","volume":"13","author":"G Tan","year":"2020","unstructured":"Tan G, Huang C, Chen J, et al. HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1\/2 pathway. J Hematol Oncol. 2020;13:149. https:\/\/doi.org\/10.1186\/s13045-020-00985-0.","journal-title":"J Hematol Oncol"},{"key":"1206_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41575-020-0326-4","volume":"17","author":"JV Patankar","year":"2020","unstructured":"Patankar JV, Becker C. Cell death in the gut epithelium and implications for chronic inflammation. Nat Rev Gastroenterol Hepatol. 2020;17:543\u201356. https:\/\/doi.org\/10.1038\/s41575-020-0326-4.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1206_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.molcel.2023.11.040","volume":"84","author":"Y Ai","year":"2024","unstructured":"Ai Y, Meng Y, Yan B, Zhou Q, Wang X. The biochemical pathways of apoptotic, necroptotic, pyroptotic, and ferroptotic cell death. Mol Cell. 2024;84(1):170\u20139. https:\/\/doi.org\/10.1016\/j.molcel.2023.11.040.","journal-title":"Mol Cell"},{"issue":"1","key":"1206_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","volume":"6","author":"P Yu","year":"2021","unstructured":"Yu P, Zhang X, Liu N, et al. Pyroptosis: mechanisms and diseases. Sig Transduct Target Ther. 2021;6(1):128. https:\/\/doi.org\/10.1038\/s41392-021-00507-5.","journal-title":"Sig Transduct Target Ther"},{"issue":"2","key":"1206_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon F, Burns K, Tschopp J. The inflammasome. Mol Cell. 2002;10(2):417\u201326. https:\/\/doi.org\/10.1016\/S1097-2765(02)00599-3.","journal-title":"Mol Cell"},{"key":"1206_CR11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nature15514","volume":"526","author":"J Shi","year":"2015","unstructured":"Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526:660\u20135. https:\/\/doi.org\/10.1038\/nature15514.","journal-title":"Nature"},{"issue":"1","key":"1206_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/834805","volume":"2015","author":"J Soderman","year":"2015","unstructured":"Soderman J, Berglind L, Almer S. Gene expression-genotype analysis implicates GSDMA, GSDMB, and LRRC3C as contributors to inflammatory bowel disease susceptibility. BioMed Res Int. 2015;2015(1):834805. https:\/\/doi.org\/10.1155\/2015\/834805.","journal-title":"BioMed Res Int"},{"issue":"6","key":"1206_CR13","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s10753-024-02025-2","volume":"47","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Ma Y, Pei J, et al. Exploring pyroptosis-related signature genes and potential drugs in ulcerative colitis by transcriptome data and animal experimental validation. Inflammation. 2024;47(6):2057\u201376.","journal-title":"Inflammation"},{"key":"1206_CR14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.immuni.2015.10.009","volume":"43","author":"D Yang","year":"2015","unstructured":"Yang D, He Y, Mu\u00f1oz-Planillo R, Liu Q, N\u00fa\u00f1ez G. Caspase-11 requires the pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock. Immunity. 2015;43:923\u201332. https:\/\/doi.org\/10.1016\/j.immuni.2015.10.009.","journal-title":"Immunity"},{"issue":"1","key":"1206_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000341681","volume":"30","author":"C Bauer","year":"2012","unstructured":"Bauer C, Duewell P, Lehr H, Endres S, Schnurr M. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig Dis. 2012;30(1):82\u201390. https:\/\/doi.org\/10.1159\/000341681.","journal-title":"Dig Dis"},{"issue":"2","key":"1206_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/ecco-jcc\/jjac121","volume":"17","author":"S Mortlock","year":"2023","unstructured":"Mortlock S, Lord A, Montgomery G, Zakrzewski M, Simms LA, Krishnaprasad K, et al. An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis. J Crohn\u2019s Colitis. 2023;17(2):277\u201388.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1206_CR17","doi-asserted-by":"publisher","first-page":"17479","DOI":"10.18632\/oncotarget.8243","volume":"7","author":"D Wei","year":"2016","unstructured":"Wei D, Guo H, Xu C, Wang B, Zhang M, Ding F. Mitochondrial reactive oxygen species-mediated NLRP3 inflammasome activation contributes to aldosterone-induced renal tubular cell injury. Oncotarget. 2016;7:17479\u201391.","journal-title":"Oncotarget"},{"key":"1206_CR18","doi-asserted-by":"publisher","DOI":"10.1530\/MAH-23-0015","author":"S Ghosh","year":"2024","unstructured":"Ghosh S, Nukavarapu S, Jala VR. Effects of heavy metals on gut barrier integrity and gut microbiota. Microb Host. 2024. https:\/\/doi.org\/10.1530\/MAH-23-0015.","journal-title":"Microb Host"},{"key":"1206_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00612","volume":"6","author":"S De Santis","year":"2015","unstructured":"De Santis S, Cavalcanti E, Mastronardi M, Jirillo E, Chieppa M. Nutritional keys for intestinal barrier modulation. Front Immunol. 2015;6:612.","journal-title":"Front Immunol"},{"key":"1206_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.998470","volume":"13","author":"K Chen","year":"2022","unstructured":"Chen K, Shang S, Yu S, et al. Identification and exploration of pharmacological pyroptosis-related biomarkers of ulcerative colitis. Front Immunol. 2022;13:998470.","journal-title":"Front Immunol"},{"key":"1206_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/7040113","volume":"2023","author":"Y Ning","year":"2023","unstructured":"Ning Y, Lin K, Fang J, et al. Pyroptosis-related signature predicts the progression of ulcerative colitis and colitis-associated colorectal cancer as well as the anti-TNF therapeutic response. J Immunol Res. 2023;2023:7040113.","journal-title":"J Immunol Res"},{"key":"1206_CR22","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3389\/fimmu.2017.01168","volume":"8","author":"AC Lei-Leston","year":"2017","unstructured":"Lei-Leston AC, Murphy AG, Maloy KJ. Epithelial cell inflammasomes in intestinal immunity and inflammation. Front Immunol. 2017;8:1168. https:\/\/doi.org\/10.3389\/fimmu.2017.01168.","journal-title":"Front Immunol"},{"issue":"1","key":"1206_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.gastro.2023.09.019","volume":"166","author":"A Gilliland","year":"2024","unstructured":"Gilliland A, Chan JJ, De Wolfe TJ, Yang H, Vallance BA. Pathobionts in inflammatory bowel disease: origins, underlying mechanisms, and implications for clinical care. Gastroenterology. 2024;166(1):44\u201358. https:\/\/doi.org\/10.1053\/j.gastro.2023.09.019.","journal-title":"Gastroenterology"},{"issue":"10","key":"1206_CR24","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1021\/acschemneuro.3c00127","volume":"14","author":"JM Sasso","year":"2023","unstructured":"Sasso JM, Ammar RM, Tenchov R, et al. Gut microbiome-brain alliance: a landscape view into mental and gastrointestinal health and disorders. ACS Chem Neurosci. 2023;14(10):1717\u201363. https:\/\/doi.org\/10.1021\/acschemneuro.3c00127.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"1206_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3748\/wjg.v24.i1.5","volume":"24","author":"ZH Shen","year":"2018","unstructured":"Shen ZH, Zhu CX, Quan YS, et al. Relationship between intestinal microbiota and ulcerative colitis: mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018;24(1):5\u201314. https:\/\/doi.org\/10.3748\/wjg.v24.i1.5.","journal-title":"World J Gastroenterol"},{"key":"1206_CR26","doi-asserted-by":"publisher","first-page":"1089600","DOI":"10.3389\/fimmu.2022.1089600","volume":"13","author":"M Zheng","year":"2023","unstructured":"Zheng M, Han R, Yuan Y, et al. The role of Akkermansia muciniphila in inflammatory bowel disease: current knowledge and perspectives. Front Immunol. 2023;13:1089600. https:\/\/doi.org\/10.3389\/fimmu.2022.1089600.","journal-title":"Front Immunol"},{"issue":"2","key":"1206_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113305","volume":"143","author":"X Xu","year":"2024","unstructured":"Xu X, Huang Z, Huang Z, et al. Butyrate attenuates intestinal inflammation in Crohn\u2019s disease by suppressing pyroptosis of intestinal epithelial cells via the cGSA-STING-NLRP3 axis. Int Immunopharmacol. 2024;143(2):113305. https:\/\/doi.org\/10.1016\/j.intimp.2024.113305.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"1206_CR28","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3748\/wjg.v22.i3.1246","volume":"22","author":"GE Tontini","year":"2016","unstructured":"Tontini GE, Rath T, Neumann H. Advanced gastrointestinal endoscopic imaging for inflammatory bowel diseases. World J Gastroenterol. 2016;22(3):1246\u201359. https:\/\/doi.org\/10.3748\/wjg.v22.i3.1246.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"1206_CR29","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tips.2024.08.003","volume":"45","author":"P Wangchuk","year":"2024","unstructured":"Wangchuk P, Yeshi K, Loukas A. Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments. Trends Pharmacol Sci. 2024;45(10):892\u2013903. https:\/\/doi.org\/10.1016\/j.tips.2024.08.003.","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"1206_CR30","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.gastrohep.2018.05.029","volume":"41","author":"J Guardiola","year":"2018","unstructured":"Guardiola J, Lobat\u00f3n T, Cerrillo E, Ferreiro-Iglesias R, Gisbert JP, Dom\u00e8nech E, et al. Recommendations of the Spanish working group on Crohn\u2019s disease and ulcerative colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol. 2018;41(8):514\u201329. https:\/\/doi.org\/10.1016\/j.gastrohep.2018.05.029.","journal-title":"Gastroenterol Hepatol"},{"issue":"6","key":"1206_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00395-020-00832-w","volume":"115","author":"X Wang","year":"2020","unstructured":"Wang X, Li X, Liu S, et al. Pcsk9 regulates pyroptosis via mtdna damage in chronic myocardial ischemia. Basic Res Cardiol. 2020;115(6):66. https:\/\/doi.org\/10.1007\/s00395-020-00832-w.","journal-title":"Basic Res Cardiol"},{"issue":"8","key":"1206_CR32","first-page":"5129","volume":"15","author":"J Yang","year":"2023","unstructured":"Yang J, Ma X, Niu D, Sun Y, Chai X, Deng Y, et al. PCSK9 inhibitors suppress oxidative stress and inflammation in atherosclerotic development by promoting macrophage autophagy. Am J Transl Res. 2023;15(8):5129\u201344.","journal-title":"Am J Transl Res"},{"issue":"9","key":"1206_CR33","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/MCG.0000000000001607","volume":"56","author":"C Marinelli","year":"2022","unstructured":"Marinelli C, Zingone F, Lupo MG, et al. Serum levels of PCSK9 are increased in patients with active ulcerative colitis representing a potential biomarker of disease activity: a cross-sectional study. J Clin Gastroenterol. 2022;56(9):787\u201393. https:\/\/doi.org\/10.1097\/MCG.0000000000001607.","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"1206_CR34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3748\/wjg.v11.i4.605","volume":"11","author":"A Wiercinska-Drapalo","year":"2005","unstructured":"Wiercinska-Drapalo A, Flisiak R, Jaroszewicz J, Prokopowicz D. Plasma interleukin-18 reflects severity of ulcerative colitis. World J Gastroenterol. 2005;11(4):605\u20138. https:\/\/doi.org\/10.3748\/wjg.v11.i4.605.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"1206_CR35","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.cell.2015.10.072","volume":"163","author":"R Nowarski","year":"2015","unstructured":"Nowarski R, Jackson R, Gagliani N, de Zoete MR, Palm NW, Bailis W, et al. Epithelial IL-18 equilibrium controls barrier function in colitis. Cell. 2015;163(6):1444\u201356. https:\/\/doi.org\/10.1016\/j.cell.2015.10.072.","journal-title":"Cell"},{"key":"1206_CR36","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00535-010-0245-1","volume":"45","author":"A Kobori","year":"2010","unstructured":"Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T, et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol. 2010;45:999\u20131007. https:\/\/doi.org\/10.1007\/s00535-010-0245-1.","journal-title":"J Gastroenterol"},{"key":"1206_CR37","doi-asserted-by":"publisher","first-page":"8017","DOI":"10.1073\/pnas.0912678107","volume":"107","author":"L Pastorelli","year":"2010","unstructured":"Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1\/Th2 driven enteritis. Proc Natl Acad Sci USA. 2010;107:8017\u201322. https:\/\/doi.org\/10.1073\/pnas.0912678107.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1206_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41423-022-00950-6","volume":"20","author":"C Chauvin","year":"2023","unstructured":"Chauvin C, Retnakumar SV, Bayry J. Gasdermin D as a cellular switch to orientate immune responses via IL-33 or IL-1\u03b2. Cell Mol Immunol. 2023;20(1):8\u201310. https:\/\/doi.org\/10.1038\/s41423-022-00950-6.","journal-title":"Cell Mol Immunol"},{"key":"1206_CR39","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","volume":"9","author":"NR Sproston","year":"2018","unstructured":"Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. https:\/\/doi.org\/10.3389\/fimmu.2018.00754.","journal-title":"Front Immunol"},{"key":"1206_CR40","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.3389\/fimmu.2020.02126","volume":"11","author":"IM Rajab","year":"2020","unstructured":"Rajab IM, Hart PC, Potempa LA. How C-reactive protein structural isoforms with distinctive bioactivities affect disease progression. Front Immunol. 2020;11:2126. https:\/\/doi.org\/10.3389\/fimmu.2020.02126.","journal-title":"Front Immunol"},{"issue":"4","key":"1206_CR41","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/ibd\/izaa088","volume":"27","author":"RK Grant","year":"2021","unstructured":"Grant RK, Jones GR, Plevris N, Lynch RW, Jenkinson PW, Lees CW, et al. The ACE (albumin, CRP and endoscopy) index in acute colitis: a simple clinical index on admission that predicts outcome in patients with acute ulcerative colitis. Inflamm Bowel Dis. 2021;27(4):451\u20137. https:\/\/doi.org\/10.1093\/ibd\/izaa088.","journal-title":"Inflamm Bowel Dis"},{"key":"1206_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12876-020-01229-8","volume":"20","author":"M Wakai","year":"2020","unstructured":"Wakai M, Hayashi R, Tanaka S, et al. Serum amyloid A is a better predictive biomarker of mucosal healing than C-reactive protein in ulcerative colitis in clinical remission. BMC Gastroenterol. 2020;20:85. https:\/\/doi.org\/10.1186\/s12876-020-01229-8.","journal-title":"BMC Gastroenterol"},{"key":"1206_CR43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/CEG.S51902","volume":"9","author":"N Walsham","year":"2016","unstructured":"Walsham N, Sherwood R. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016;9:21\u20139. https:\/\/doi.org\/10.2147\/CEG.S51902.","journal-title":"Clin Exp Gastroenterol"},{"key":"1206_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.833588","volume":"13","author":"S Zhang","year":"2022","unstructured":"Zhang S, Liang Y, Yao J, Li D, Wang L. Role of pyroptosis in inflammatory bowel disease (IBD): from gasdermins to DAMPs. Front Pharmacol. 2022;13:833588. https:\/\/doi.org\/10.3389\/fphar.2022.833588.","journal-title":"Front Pharmacol"},{"key":"1206_CR45","doi-asserted-by":"publisher","first-page":"13513","DOI":"10.1038\/s41598-024-63893-0","volume":"14","author":"S Heinzel","year":"2024","unstructured":"Heinzel S, Jureczek J, Kainulainen V, Nieminen A, Suenkel U, Thaler A, et al. Elevated fecal calprotectin is associated with gut microbial dysbiosis, altered serum markers and clinical outcomes in older individuals. Sci Rep. 2024;14:13513. https:\/\/doi.org\/10.1038\/s41598-024-63893-0.","journal-title":"Sci Rep"},{"issue":"6","key":"1206_CR46","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/j.1572-0241.2003.07458.x","volume":"98","author":"SV Kane","year":"2003","unstructured":"Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98(6):1309\u201314. https:\/\/doi.org\/10.1111\/j.1572-0241.2003.07458.x.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1206_CR47","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1159\/000515432","volume":"39","author":"D Sorrentino","year":"2021","unstructured":"Sorrentino D, Nguyen VQ, Love K. Fecal lactoferrin predicts primary nonresponse to biologic agents in inflammatory bowel disease. Dig Dis. 2021;39(6):626\u201333. https:\/\/doi.org\/10.1159\/000515432.","journal-title":"Dig Dis"},{"issue":"5","key":"1206_CR48","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4291\/wjgp.v10.i5.54","volume":"10","author":"MG Rubio","year":"2019","unstructured":"Rubio MG, Amo-Mensah K, Gray JM, Nguyen VQ, Nakat S, Grider D, et al. Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2019;10(5):54\u201363. https:\/\/doi.org\/10.4291\/wjgp.v10.i5.54.","journal-title":"World J Gastrointest Pathophysiol"},{"key":"1206_CR49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-024-01801-8","volume":"9","author":"C Zhu","year":"2024","unstructured":"Zhu C, Xu S, Jiang R, et al. The gasdermin family: emerging therapeutic targets in diseases. Sig Transduct Target Ther. 2024;9:87. https:\/\/doi.org\/10.1038\/s41392-024-01801-8.","journal-title":"Sig Transduct Target Ther"},{"issue":"9","key":"1206_CR50","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.apsb.2021.02.006","volume":"11","author":"BE Burdette","year":"2021","unstructured":"Burdette BE, Esparza AN, Zhu H, Wang S. Gasdermin D in pyroptosis. Acta Pharm Sin B. 2021;11(9):2768\u201382. https:\/\/doi.org\/10.1016\/j.apsb.2021.02.006.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"1206_CR51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/gastro\/goy011","volume":"6","author":"Y Yuan","year":"2018","unstructured":"Yuan Y, Xie K, Wang S, Yuan L. Inflammatory caspase-related pyroptosis: mechanism, regulation, and therapeutic potential for inflammatory bowel disease. Gastroenterol Rep. 2018;6(3):167\u201376. https:\/\/doi.org\/10.1093\/gastro\/goy011.","journal-title":"Gastroenterol Rep"},{"key":"1206_CR52","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41467-023-44669-y","volume":"15","author":"F Ma","year":"2024","unstructured":"Ma F, Ghimire L, Ren Q, et al. Gasdermin E dictates inflammatory responses by controlling the mode of neutrophil death. Nat Commun. 2024;15:386. https:\/\/doi.org\/10.1038\/s41467-023-44669-y.","journal-title":"Nat Commun"},{"issue":"12","key":"1206_CR53","doi-asserted-by":"publisher","first-page":"10172","DOI":"10.3390\/ijms241210172","volume":"24","author":"A Korta","year":"2023","unstructured":"Korta A, Kula J, Gomu\u0142ka K. The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease. Int J Mol Sci. 2023;24(12):10172. https:\/\/doi.org\/10.3390\/ijms241210172.","journal-title":"Int J Mol Sci"},{"key":"1206_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac034","author":"GW Sewell","year":"2022","unstructured":"Sewell GW, Kaser A. Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention. J Crohn Colitis. 2022. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac034.","journal-title":"J Crohn Colitis"},{"issue":"4","key":"1206_CR55","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.dld.2018.10.013","volume":"51","author":"A Viola","year":"2019","unstructured":"Viola A, Pugliese D, Renna S, Furfaro F, Caprioli F, D\u2019Inc\u00e0 R, et al. Outcome in ulcerative colitis after switch from adalimumab\/golimumab to infliximab: a multicenter retrospective study. Dig Liver Dis. 2019;51(4):510\u20135. https:\/\/doi.org\/10.1016\/j.dld.2018.10.013.","journal-title":"Dig Liver Dis"},{"issue":"29","key":"1206_CR56","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.3748\/wjg.v29.i29.4481","volume":"29","author":"L Wang","year":"2023","unstructured":"Wang L, Chen P, He S, Duan S, Zhang Y. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: a literature review. World J Gastroenterol. 2023;29(29):4481\u201398. https:\/\/doi.org\/10.3748\/wjg.v29.i29.4481.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"1206_CR57","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/00054725-200606000-00013","volume":"12","author":"MR Konikoff","year":"2006","unstructured":"Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(6):524\u201334. https:\/\/doi.org\/10.1097\/00054725-200606000-00013.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"1206_CR58","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a036392","volume":"12","author":"NM de Vasconcelos","year":"2020","unstructured":"de Vasconcelos NM, Lamkanfi M. Recent insights on inflammasomes, Gasdermin pores, and pyroptosis. Cold Spring Harb Perspect Biol. 2020;12(5):a036392. https:\/\/doi.org\/10.1101\/cshperspect.a036392.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1206_CR59","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature18629","volume":"535","author":"X Liu","year":"2016","unstructured":"Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016;535:153\u2013215. https:\/\/doi.org\/10.1038\/nature18629.","journal-title":"Nature"},{"key":"1206_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat2738","author":"JK Rathkey","year":"2018","unstructured":"Rathkey JK, Zhao J, Liu Z, Chen Y, Yang J, Kondolf HC, et al. Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. Sci Immunol. 2018. https:\/\/doi.org\/10.1126\/sciimmunol.aat2738.","journal-title":"Sci Immunol"},{"key":"1206_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101845","volume":"70","author":"B Zhou","year":"2023","unstructured":"Zhou B, Abbott DW. Chemical modulation of gasdermin D activity: therapeutic implications and consequences. Semin Immunol. 2023;70:101845. https:\/\/doi.org\/10.1016\/j.smim.2023.101845.","journal-title":"Semin Immunol"},{"key":"1206_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0669-6","author":"JJ Hu","year":"2020","unstructured":"Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol. 2020. https:\/\/doi.org\/10.1038\/s41590-020-0669-6.","journal-title":"Nat Immunol"},{"issue":"9","key":"1206_CR63","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.7150\/thno.81571","volume":"13","author":"W Zhou","year":"2023","unstructured":"Zhou W, Zhang H, Huang L, Sun C, Yue Y, Cao X, et al. Disulfiram with Cu2+ alleviates dextran sulfate sodium-induced ulcerative colitis in mice. Theranostics. 2023;13(9):2879\u201395. https:\/\/doi.org\/10.7150\/thno.81571.","journal-title":"Theranostics"},{"issue":"18","key":"1206_CR64","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1002\/cam4.3346","volume":"9","author":"H Hu","year":"2020","unstructured":"Hu H, Cui L, Lu J, Wei K, Wei J, Li S, et al. Intestinal microbiota regulates anti-tumor effect of disulfiram combined with Cu2+ in a mice model. Cancer Med. 2020;9(18):6791\u2013801. https:\/\/doi.org\/10.1002\/cam4.3346.","journal-title":"Cancer Med"},{"key":"1206_CR65","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1126\/science.abb9818","volume":"369","author":"F Humphries","year":"1979","unstructured":"Humphries F, Shmuel-Galia L, Ketelut-Carneiro N, Li S, Wang B, Nemmara VV, et al. Succination inactivates gasdermin D and blocks pyroptosis. Science. 1979;369:1633\u20137. https:\/\/doi.org\/10.1126\/science.abb9818.","journal-title":"Science"},{"issue":"3","key":"1206_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70263","volume":"15","author":"X Fan","year":"2025","unstructured":"Fan X, Cheng Z, Shao R, Ye K, Chen X, Cai X, et al. The novel GSDMD inhibitor GI-Y2 exerts antipyroptotic effects to reduce atherosclerosis. Clin Transl Med. 2025;15(3):e70263. https:\/\/doi.org\/10.1002\/ctm2.70263.","journal-title":"Clin Transl Med"},{"issue":"5","key":"1206_CR67","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1039\/c9md00059c","volume":"10","author":"A Pandeya","year":"2019","unstructured":"Pandeya A, Li L, Li Z, Wei Y. Gasdermin D (GSDMD) as a new target for the treatment of infection. Medchemcomm. 2019;10(5):660\u20137. https:\/\/doi.org\/10.1039\/c9md00059c.","journal-title":"Medchemcomm"},{"key":"1206_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109058","volume":"111","author":"N Wang","year":"2022","unstructured":"Wang N, Kong R, Han W, Bao W, Shi Y, Ye L, et al. Honokiol alleviates ulcerative colitis by targeting PPAR-\u03b3-TLR4-NF-\u03baB signaling and suppressing gasdermin-D-mediated pyroptosis in vivo and in vitro. Int Immunopharmacol. 2022;111:109058. https:\/\/doi.org\/10.1016\/j.intimp.2022.109058.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1206_CR69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1152\/physiolgenomics.00081.2022","volume":"55","author":"W Yuan","year":"2023","unstructured":"Yuan W, Tian Y, Lin C, Wang Y, Liu Z, Zhao Y, et al. Pectic polysaccharides derived from Hainan Rauwolfia ameliorate NLR family pyrin domain-containing 3-mediated colonic epithelial cell pyroptosis in ulcerative colitis. Physiol Genomics. 2023;55(1):27\u201340. https:\/\/doi.org\/10.1152\/physiolgenomics.00081.2022.","journal-title":"Physiol Genomics"},{"issue":"4","key":"1206_CR70","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000560","volume":"14","author":"C Apolit","year":"2023","unstructured":"Apolit C, Campos N, Vautrin A, Begon-Pescia C, Lapasset L, Scherrer D, et al. ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases. Clin Transl Gastroenterol. 2023;14(4):e00560. https:\/\/doi.org\/10.14309\/ctg.0000000000000560.","journal-title":"Clin Transl Gastroenterol"},{"issue":"11","key":"1206_CR71","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/S2468-1253(22)00233-3","volume":"7","author":"S Vermeire","year":"2022","unstructured":"Vermeire S, Sands BE, Tilg H, Tulassay Z, Kempinski R, Danese S, et al. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. Lancet Gastroenterol Hepatol. 2022;7(11):1024\u201335. https:\/\/doi.org\/10.1016\/S2468-1253(22)00233-3.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"1206_CR72","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2174\/0127724328245156231008154045","volume":"19","author":"MA Bhat","year":"2024","unstructured":"Bhat MA, Usman I, Dhaneshwar S. Application of drug repurposing approach for therapeutic intervention of inflammatory bowel disease. Curr Rev Clin Exp Pharmacol. 2024;19(3):234\u201349. https:\/\/doi.org\/10.2174\/0127724328245156231008154045.","journal-title":"Curr Rev Clin Exp Pharmacol"},{"issue":"9","key":"1206_CR73","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1021\/acs.jafc.0c06755","volume":"69","author":"X Wang","year":"2021","unstructured":"Wang X, Gao Y, Wang L, Yang D, Bu W, Gou L, et al. Troxerutin improves dextran sulfate sodium-induced ulcerative colitis in mice. J Agric Food Chem. 2021;69(9):2729\u201344. https:\/\/doi.org\/10.1021\/acs.jafc.0c06755.","journal-title":"J Agric Food Chem"},{"issue":"8","key":"1206_CR74","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tips.2022.04.003","volume":"43","author":"RC Coll","year":"2022","unstructured":"Coll RC, Schroder K, Pelegr\u00edn P. Nlrp3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci. 2022;43(8):653\u201368. https:\/\/doi.org\/10.1016\/j.tips.2022.04.003.","journal-title":"Trends Pharmacol Sci"},{"issue":"16","key":"1206_CR75","doi-asserted-by":"publisher","first-page":"1573684","DOI":"10.3389\/fphar.2025.1573684","volume":"9","author":"X Lu","year":"2025","unstructured":"Lu X, Sun Y, Zhang Z, Sun Z, Wang S, Xu E. Regulation of pyroptosis by natural products in ulcerative colitis: mechanisms and therapeutic potential. Front Pharmacol. 2025;9(16):1573684. https:\/\/doi.org\/10.3389\/fphar.2025.1573684.","journal-title":"Front Pharmacol"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01206-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-025-01206-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-025-01206-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:37:22Z","timestamp":1764740242000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-025-01206-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1206"],"URL":"https:\/\/doi.org\/10.1186\/s12929-025-01206-x","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}